Cerus Value Stock - Dividend - Research Selection
Market price: 5,35 USD
Cerus Fundamental data and company key figures of the share
|Annual reports in USD|
|Net operating cash flow||-40.743.000|
|Free cash flow||-42.358.000|
|Liabilities & Shareholders equity||221.415.000|
|Diluted shares outstanding||168.170.000|
✓ NEW Fundamental API Access to 500 data points per month
✓ Fundamental data up to 25 years
✓ Comparison to all other stocks by the FScore
✓ Time saving!
How our site works ...
✓ Non-binding 7 days without automatic subscription
✓ No termination required after the free week
✓ Finanzoo fundamental analysis
✓ Data updated daily
✓ Virtual depots
✓ Share alarms via email
✓ Subscription can be canceled at any time at the end of the month
✓ Choice of desired shares
✓ Over 2000 stock analyzes available
✓ Bitcoin payment possible if you do not want to subscribe
Price for monthly subscription $ 19.99 / month including VAT.
|Market Capitalization||945.115.392,00 USD|
|Raw Data Source||US GAAP in Millionen USD|
Description of the company
Cerus Corporation is a biomedical products company focused on commercializing the INTERCEPT Blood System to enhance blood safety. The INTERCEPT Blood System, which is based on the Company´s technology for controlling biological replication, is designed to inactivate blood-borne pathogens in donated blood components intended for transfusion. The Company has worldwide rights for its intercepts Blood System for three blood components: platelets, plasma and red blood cells. The INTERCEPT Blood System for platelets, or platelet system, and the INTERCEPT Blood System for plasma, or plasma system, have received Conformite Europeene (CE) marks and are being marketed and sold in a number of countries in Europe, The Commonwealth of Independent States, the Middle East and selected countries in other regions worldwide. The Company sells both the platelet and plasma systems using its direct sales force and through distributors.